關節止痛注射市場規模、佔有率、成長分析，按類型、關節、最終用途、地區 - 產業預測，2024-2031

2022年全球關節疼痛注射市場規模估值為63億美元，從2023年的67.9億美元成長到2031年的122.8億美元，在預測期內（2024-2031年）預計複合年成長率為7.7。 。

由於關節疾病盛行率上升、人口老化以及對微創治療的需求不斷增加，全球關節疼痛注射市場預計將顯著成長。這些注射不僅可以緩解針對性疼痛，還可以增強關節功能，使其成為手術的理想替代方案。旨在提高功效和壽命的注射技術和新配方的創新正在進一步推動市場擴張。再生醫學和生物注射療法的日益接受度也正在改變市場動態。然而，高成本、有限的報銷選擇和潛在副作用等挑戰可能會阻礙未來的成長前景。總體而言，由於不斷變化的患者需求和技術進步，該行業提供了巨大的商機。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

關節痛注射劑市場規模：按類型

• 市場概況
• 玻尿酸注射
• 皮質類固醇注射
• 富血小板血漿注射
• 其他

關節痛注射劑市場規模：依關節分類

• 市場概況
• 膝蓋
• 肩膀和肘部
• 腳踝和臀部
• 其他接頭類型

關節痛注射劑市場規模：依最終用途分類

• 市場概況
• 醫院
• 診所
• 其他

關節痛注射劑市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Pfizer Inc.（USA）
• AbbVie Inc.（USA）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sanofi（France）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Seikagaku Corporation（Japan）
• Anika Therapeutics, Inc.（USA）
• Ferring BV（Netherlands）
• Bioventus（USA）
• Flexion Therapeutics, Inc.（USA）
• Zimmer Biomet Holdings, Inc.（USA）
• Smith & Nephew plc（UK）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）

結論和建議

Global Joint Pain Injections Market size was valued at USD 6.3 billion in 2022 and is poised to grow from USD 6.79 billion in 2023 to USD 12.28 billion by 2031, growing at a CAGR of 7.7% during the forecast period (2024-2031).

The global Joint Pain Injections market is poised for substantial growth, fueled by a rising incidence of joint disorders, an aging population, and an escalating demand for minimally invasive treatments. These injections not only deliver targeted pain relief but also enhance joint functionality, serving as a preferable alternative to surgery. Innovations in injection technologies and novel formulations aimed at improving efficacy and longevity are further propelling market expansion. The increasing acceptance of regenerative medicine and biologic injection therapies is also transforming the market dynamics. Nonetheless, challenges such as high costs, limited reimbursement options, and potential side effects could impede future growth prospects. Overall, this sector presents significant opportunities driven by evolving patient needs and technological advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Joint Pain Injections market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Joint Pain Injections Market Segmental Analysis

Global Joint Pain Injections Market is segmented by type, joint, end use and region. Based on type, the market is segmented into hyaluronic acid injections, corticosteroid injections, platelet rich plasma injections and others. Based on joint, the market is segmented into knee, shoulder & elbow, ankle & hip and other joint types. Based on end use, the market is segmented into hospitals, clinics and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Joint Pain Injections Market

A key factor propelling the global Joint Pain Injections market is the rising prevalence of joint-related disorders. The escalating rates of conditions like osteoarthritis and rheumatoid arthritis have led to heightened demand for efficient pain relief treatments, particularly joint pain injections. Additionally, the aging population, coupled with increasingly sedentary lifestyles and the frequency of sports-related injuries, further fuels this market expansion. As more individuals seek effective methods to manage their joint pain, the market for joint pain injections continues to grow, reflecting a significant need for innovative and targeted therapeutic options in the healthcare landscape.

Restraints in the Global Joint Pain Injections Market

One significant restraint on the global Joint Pain Injections market is the elevated cost associated with these treatments. For many individuals, particularly those lacking adequate insurance coverage, the price of joint pain injections can be prohibitively high. This financial barrier restricts access to necessary treatment options for patients, notably in developing regions where healthcare affordability poses a considerable challenge. Furthermore, the reimbursement policies and regulatory obstacles present in certain countries can further impede market expansion, limiting the availability and acceptance of joint pain injections among potential users. Overall, these factors contribute to a constrained market environment.

Market Trends of the Global Joint Pain Injections Market

The global Joint Pain Injections market is witnessing a significant trend towards the adoption of minimally invasive procedures, driven by a burgeoning demand for non-surgical treatment options among patients and healthcare providers. This shift towards injections is fueled by their advantages, such as quicker recovery times, lower complication risks, and reduced postoperative discomfort. Administered in outpatient settings, these injections deliver targeted pain relief directly to the affected joints, enhancing patient comfort and satisfaction. Furthermore, the trend reflects a broader movement towards personalized and patient-centric care, enabling customized treatment plans that cater to individual patient needs and preferences, ultimately fostering a more proactive approach to managing joint pain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Joint Pain Injections Market Size by Type & CAGR (2024-2031)

• Market Overview
• Hyaluronic Acid Injections
• Corticosteroid Injections
• Platelet Rich Plasma Injections
• Others

Global Joint Pain Injections Market Size by Joint & CAGR (2024-2031)

• Market Overview
• Knee
• Shoulder & Elbow
• Ankle & Hip
• Other Joint Types

Global Joint Pain Injections Market Size by End Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Other

Global Joint Pain Injections Market Size & CAGR (2024-2031)

• North America (Type, Joint, End Use)
  • USA
  • Canada
• Europe (Type, Joint, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Joint, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Joint, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Joint, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioventus (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations